| Ytd | -22.85% | |
| 1y | -33.69% |
| Open | 2.81 | Prev Close | 2.82 | Low | 2.79 | High | 2.87 | Mkt Cap | 248.89M |
| Vol | 732.25K | Avg Vol | 4.40M | EPS | -0.93 | P/E | -3.03 | Forward P/E | -5.14 |
| Beta | 0.25 | Short Ratio | 5.81 | Inst. Own | 56.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 01-20 | Earning | 08-11 | 50-d Avg | 2.90 | 200-d Avg | 3.81 | 1yr Est | 22.86 |
ALT News
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook art
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may pr
Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperf
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc
Altimmune NASDAQ: ALT management used an appearance at the Goldman Sachs Global Healthcare Conferenc
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 da
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set
Altimmune NASDAQ: ALT executives said the company is preparing to begin enrolling patients in the se
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or d
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data
“Best of EASL” oral presentation highlights meaningful reductions in triglycerides, cholesterol, and
GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-s
Concurrent improvement across key non-invasive tests underscores convergence of pemvidutide effects
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA
ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash run
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl
Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks decl
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as t
On Friday, 1043 companies hit new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
Stocks Which Set New 52-Week Low Yesterday, October 11th
Are Hedge Fund ETFs Worth The Trouble?